TriSalus Life Sciences

TriSalus Life Sciences, Inc. is an oncology-focused medical technology company developing drug delivery systems and immuno-oncology therapies for difficult-to-treat liver and pancreatic cancers. Its current product portfolio centers on Pressure-Enabled Drug Delivery (PEDD) platforms, including the TriNav infusion system for hepatic arterial procedures and the Pancreatic Retrograde Venous Infusion device. TriSalus also advances nelitolimod, an investigational immunotherapeutic designed to work alongside standard treatments in solid tumors. The company’s products and clinical programs are aimed at improving how therapies reach tumor sites, particularly where conventional delivery faces anatomical and physiological barriers. TriSalus Life Sciences, Inc. serves the interventional oncology and medical device markets, combining device-based delivery with oncology therapeutics to support physicians treating liver cancer, liver metastases, and pancreatic tumors.